1. ALLA AKTIER
  2. NYHETER
  3. Q-LINEA

Q-Linea

Nyheter Q-Linea Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Q-linea publish the Annual report for 2023

REG

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), announced today that the Annual Report for the 2023 fiscal year has been published.

The Annual Report is attached and can also be downloaded from the company’s website, www.qlinea.com.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information is information that Q-linea is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-12 08:00 CEST.

Attachments

Qlinea 2023 ENG
Q-linea-2023-12-31-sv

Datum 2024-04-12, kl 08:00
Källa MFN
Bifogade filer
Qlinea 2023 ENG
Q-linea-2023-12-31-sv